title: Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
abstract: Atypical antipsychotic-induced hyperprolactinemia can cause important clinical symptoms, particularly in young women and also in men, such as impotence, loss of libido, gynecomastia, anovulation and galactorrhea.
  
  
  METHODS
  Observational over one-year follow-up of six patients (four women and two men, mean age of 31.1 years, range 26-37), treated with different atypical antipsychotics in an outpatient psychiatric device, who had clinical complications associated to high prolactin serum levels. All of them were treated with standard doses of cabergoline.
  
  
  RESULTS
  Most patients experienced significant clinical improvement after treatment with standard doses of cabergoline (mean dosage 1.08 mg/week), maintained for a mean of 18 month. Normal prolactin levels were achieved after the first months of treatment with cabergoline. No side effects or worsening of psychotic or behavioral symptoms were observed.
  
  
  CONCLUSIONS
  Long-term treatment with cabergoline seems to be safe in atypical antipsychotic-treated patients.
authors.affiliation: Department of Psychiatry, Corporació Sanitária i Universitária Parc Taulí, Sabadell, Barcelona, Spain.
authors.forename: Ramón
authors.initials: R
authors.lastname: Coronas
authors.forename: Jesús
authors.initials: J
authors.lastname: Cobo
authors.forename: Olga
authors.initials: O
authors.lastname: Giménez-Palop
authors.forename: Emilio
authors.initials: E
authors.lastname: Ortega
authors.forename: Manel
authors.initials: M
authors.lastname: Márquez
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline